Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors
A phase 2 trial of Tisotumab vedotin, Pembrolizumab, Carboplatin and Cisplatin in colorectal cancer, non-small-cell lung cancer, pancreatic ductal adenocarcinoma and head and neck squamous cell carcinoma, run by Seagen, a wholly owned subsidiary of Pfizer, active and no longer recruiting.
Overview
Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors is a phase 2 interventional study registered as NCT03485209 by Seagen, a wholly owned subsidiary of Pfizer, with 350 participants enrolled, started 2018-06-25 and due to reach its primary completion in 2026-03-20. Interventions recorded: tisotumab vedotin, pembrolizumab, carboplatin and cisplatin.
Similar pages
not linked directly; found by shared links- TrialStudy of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
Shares Cisplatin, Merck & Co. (MSD), Carboplatin, Pembrolizumab and the tag pipeline.
- TrialStudy of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)
Shares Cisplatin, Merck & Co. (MSD), Carboplatin, Pembrolizumab and the tag pipeline.
- TrialA Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
Shares Cisplatin, Merck & Co. (MSD), Carboplatin, Pembrolizumab and the tag pipeline.
- TrialStudy of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)
Shares Cisplatin, Merck & Co. (MSD), Carboplatin, Pembrolizumab and the tag pipeline.
- TrialStudy of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)
Shares Cisplatin, Merck & Co. (MSD), Carboplatin, Pembrolizumab and the tag pipeline.
- TrialA Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
Shares Cisplatin, Carboplatin, Head and neck squamous cell carcinoma, Pembrolizumab and the tag pipeline.
- TrialA Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
Shares Merck & Co. (MSD), Head and neck squamous cell carcinoma, Pembrolizumab, Non-small-cell lung cancer and the tag pipeline.
- TrialPembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)
Shares Cisplatin, Merck & Co. (MSD), Carboplatin, Pembrolizumab and the tag pipeline.